Hong Kong Stock Movement
XUANZHUBIO-B rose 17.90%. Based on recent key news:
<ol>
<li>
On April 20, XUANZHUBIO presented the Phase III clinical study results of Dirocaftor for treating advanced non-small cell lung cancer with anaplastic lymphoma kinase positivity at the American Association for Cancer Research annual meeting, showing significant efficacy advantages, which drove the stock price up. Data indicated that the median progression-free survival in the Dirocaftor group was 31.3 months, significantly better than the control group's 12.9 months, with a 53% reduction in the risk of disease progression. Source: Economic Information Daily
</li>
<li>
On April 20, XUANZHUBIO released preliminary results of the NG-350A Phase 1b FORTRESS study, showing potential in treating locally advanced rectal cancer, with an overall response rate of 50% and no serious adverse events reported. This news further boosted market confidence. Source: Zhitong Finance
</li>
<li>
On April 20, XUANZHUBIO's technical signals indicated a buy, and the market held a positive attitude towards its innovative drug development capabilities, driving the stock price up. Source: Zhitong Finance The biopharmaceutical industry's innovative drug development is active.
</li>
</ol>
Stocks with High Trading Volume in the Industry
Hengrui Medicine rose 4.94%. Based on recent key news:
<ol>
<li>
On April 22, Hengrui Medicine announced its first-quarter results, with net profit increasing by 21.78% year-on-year, and the proportion of innovative drug sales significantly rising, driving the stock price up. The company achieved operating revenue of 8.141 billion yuan, with innovative drug sales revenue of 4.526 billion yuan, a year-on-year increase of 25.75%. Source: Zhitong Finance
</li>
<li>
On April 22, multiple innovative drugs from Hengrui Medicine were approved for market launch, further enhancing market confidence. This includes the world's first anti-PD-L1/TGF-βRII bispecific antibody fusion protein, Relatlimab injection. Source: Huigang Communications
</li>
<li>
On April 21, Hengrui Medicine was included in the Hong Kong SAR government's list of key enterprises for introduction, aiding its layout in Hong Kong and enhancing market recognition. Source: Viewpoint Network Innovative drug sales have significantly increased, boosting market confidence.
</li>
</ol>
Shiyao Group rose 0.11%. Based on recent key news:
<ol>
<li>
On April 20, Shiyao Group announced that its subsidiary's clinical study of injectable Sirolimus (albumin-bound) for treating advanced malignant perivascular epithelioid cell tumors has reached the primary efficacy endpoint, demonstrating excellent efficacy and is expected to become the first standard treatment option in the country, driving the stock price up. Source: Zhitong Finance
</li>
<li>
On April 22, the KN026 combined injectable Docetaxel developed in collaboration with Kangning Jiere achieved significant results in breast cancer clinical research, enhancing market confidence in Shiyao Group's R&amp;D capabilities. Source: Economic Information Daily
</li>
<li>
On April 20, Shiyao Group's HB1901 received breakthrough therapy designation from the National Medical Products Administration, further consolidating its market position. Source: Zhitong Finance Significant progress in innovative therapies in the pharmaceutical industry
Hansoh Pharmaceutical rose by 0.45%. Based on recent news,
</li>
<li>
On April 20, the MSCI China Healthcare Index has increased by 12.3% year-to-date, outperforming the MSCI China Index by 13.6%. The Chinese government work report lists biomedicine as an emerging pillar industry, and under policy catalysis, the sector's risk appetite has moderately recovered, benefiting Hansoh Pharmaceutical's rise. Source: Zhitong Finance
</li>
<li>
On April 20, CMB International released a report giving Hansoh Pharmaceutical a &#34;Buy&#34; rating with a target price of HKD 46.41. The report pointed out that breakthroughs in AI pharmaceutical technology and the overseas expansion of Chinese innovative drugs create a dual resonance, with expectations for the industry fundamentals to accelerate positively. Source: Zhitong Finance
</li>
<li>
On April 20, CSC Financial maintained a &#34;Buy&#34; rating for Hansoh Pharmaceutical with a target price of HKD 48.73. Analysts unanimously believe that Hansoh Pharmaceutical has a promising outlook, and market confidence has strengthened. Source: CSC Financial. The model for Chinese innovative drugs going overseas is diversifying, with policy support.
</li>
</ol>
Stocks ranked among the top in industry market capitalization
China Biologic Pharmaceutical fell by 1.20%. Based on recent key news:
<ol>
<li>
On April 20, China Biologic Pharmaceutical announced that its subsidiary, Chongqing Zhifei Biological Products, has received marketing approval from the National Medical Products Administration of China for the innovative drug Bemarituzumab in combination with Anlotinib for the treatment of advanced alveolar soft part sarcoma. This approval brings new market opportunities for the company; however, the stock price did not rise as a result.
</li>
<li>
On April 22, China Biologic Pharmaceutical presented the latest preclinical research data for two new generation antibody-drug conjugates at the American Association for Cancer Research annual meeting, showing good efficacy and safety, laying the foundation for subsequent clinical development. Despite this news demonstrating the company's R&amp;D strength, the stock price still declined.
</li>
<li>
On April 22, the company spent HKD 10.0238 million to repurchase 1.72 million shares at a price of HKD 5.82-5.84 per share. Repurchase actions are generally seen as a vote of confidence in the company's stock, but they failed to prevent the stock price from falling. The pharmaceutical industry's innovative drug R&amp;D is active, with significant market volatility
</li>
</ol>

02575

XUANZHUBIO-B rose 17.90%; Heng Rui Medicine rose 4.94%, with a transaction amount reaching HKD 240 million; Stone Pharmaceutical Group rose 0.11%, with a transaction amount reaching HKD 161 million; Hansoh Pharmaceutical rose 0.45%, with a transaction amount reaching HKD 122 million; China Biologic Products fell 1.20%, with a market value of HKD 108 billion

Hong Kong Stock Movement: XUANZHUBIO-B rises 17.90%, clinical research shows significant efficacy boosting market confidence